CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer By Ogkologos - August 14, 2025 583 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CT041-ST-01 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer EMA Recommends Extension of Therapeutic Indications for Asciminib MOST POPULAR Ex-NFL Player Pays For 500 Mammograms To Honor Late Mom Who... October 22, 2019 Neoadjuvant Chemotherapy with mFOLFIRINOX Followed by Chemoradiotherapy Improves Survival in Patients... August 14, 2024 How to Cope With Panic Attacks During Cancer July 12, 2022 Whole-Genome Sequencing Provides Rapid and Accurate Genomic Profiling in Patients with... March 11, 2021 Load more HOT NEWS EMA Recommends Extending Indications for Lisocabtagene Maraleucel New on NCI’s Websites for November 2021 What to Know About At-Home DNA Tests for Detecting Cancer Risk A Safer, Better Treatment Option for Some Younger Women with Breast...
